



CRS IPEC Americas Summit

Overview of administration of biologics

Simon Mattoori, PhD

Professor, Université de Montréal

Chair, CRS Focus Group Skin & Mucosal Delivery

simon.matoori@umontreal.ca

Agenda: Morning session (I)

Introductory talks

8:30 AM & 8:35 AM

Welcome, Logistics, Intro & Overview of administration of biologics: past, present, future
Simon Matoori, Université de Montréal

8:35 AM

Biologics Summit Part 1 review and key learnings
Nigel Langley, Gaylord Chemical & IPEC-Americas

9:05 AM

Introduction to high dose/high volume SC administration of biologics and the SC Delivery Consortium
Beate Bittner, F. Hoffmann - La Roche Ltd

Agenda: Morning session (II)

New technologies in high dose/high volume SC delivery

9:30 AM

Crash Course on High Dose/High Volume Subcutaneous Delivery with Recombinant Human Hyaluronidase (rHuPH20)
Marie Printz, Halozyme

10:20 AM

Microclassification™ suspensions of biologics for SC delivery of high concentration formulations
Deborah Bitterfield, Lindy Biosciences

10:50 AM

An injectable hydrogel particle platform enabling high concentration delivery of amorphous solid and crystalline biologics
Patrick Doyle, MIT

11:20 AM

XERIJECT formulation technology for SC delivery of ultra-high concentration biologics
Rick Fitch, Xeris Pharmaceuticals

Agenda: afternoon session

Predicting SC bioavailability

1:00 PM

Prediction of clinical SC bioavailability: relevance of in vivo models

Beate Bittner, F. Hoffman - La Roche

1:30 PM

How Aggregated Clinical Data Can Provide Greater Utility than Animal Models for Predicting Antibody Subcutaneous PK

Ryan Nolan, Halozyme

2:00 PM

Uncloaking In-vitro Subcutaneous Bioavailability Tools

Manuel Sanchez-Felix, Novartis

2:30 PM

Predicting Subcutaneous Drug Absorption via Machine Learning Attempts and A Custom In Vitro Device




Hao Lou, University of Kansas

3:15 PM & 4:00 PM

Panel Discussion & Conclusion


Simon Mattoori, Université de Montréal

Therapeutic modalities




Antibody

- Made of amino acids
- Glycation
- Highly charged
- High molecular weight (ca. 150 kDa)
- High affinity to epitope
 - Mono- or bispecific
- Can be covalently coupled to low Mw drugs (antibody-drug conjugate)
- Antibody fragments
- Currently over 100 FDA-approved monoclonal antibodies



Most sold pharmaceuticals 2022

Leading pharmaceutical products by sales worldwide in 2022 (in billion U.S. dollars)



Routes of administration

Parenteral route

- Intravenous
- Intramuscular
- Subcutaneous
- Intradermal
- Intrathecal
- Intraarticular
- Intraperitoneal

Enteral route


- Oral
- Sublingual
- Buccal
- Rectal

Topical route

- Transdermal
- Nasal
- Pulmonary

Most sold pharmaceuticals 2022

Leading pharmaceutical products by sales worldwide in 2022 (in billion U.S. dollars)



SC

iv

SC

SC

Parenteral route

	Intravenous	Intramuscular	Subcutaneous
	Peripheral veins	Muscles (deltoid, triceps)	Abdomen, legs, arms
Invasiveness	High	High	Low
Self-administration	Not possible	Not possible	Possible
Bioavailability	High	Medium	Low-high
Absorption rate	Fast	Medium	Slow-fast

Non-invasive routes

Enteral route

Oral

Non-invasive

Extended release (hours)

Large drug amounts

Bioavailability can be low/variable

- Degradation of drugs in GI tract
- Low absorption due to epithelial barrier
- First pass metabolism

Prolonged release (days) challenging

Only if patient can swallow

Topical route

Transdermal

Non-invasive

Extended release (hours to days)

No first-pass metabolism


Also for patients who cannot swallow

Bioavailability can be low/variable

- Degradation of drugs in skin
- Low absorption due to epithelial barrier

Low/moderate drug loading capacity


Antibody administration



CRS Skin & Mucosal Delivery Focus Group

- One of seven FG of the Controlled Release Society
- Over 250 members from academia, industry, and governmental organizations
- Aims
 - To be a leading forum to impact the forefront of delivery science specific to **skin and mucosal barriers**
 - To provide a dynamic platform, for like-minded professionals at all stages of their careers from academia, industry, and government, to
 - foster collaborations
 - enable networking opportunities and the exchange of ideas at the forefront of the field
 - increase member visibility and participation in the CRS and SMD FG
- Activities
 - Monthly webinars on skin and mucosal delivery with speakers from industry and academia
 - Member of the month
 - Scientific session at CRS annual meeting
 - Networking event at CRS annual meeting
- Currently setting up an industry subteam (Jill Steinbach-Rankins)

CRS Skin & Mucosal Delivery Focus Group



INTRODUCING OUR BOARD MEMBERS



Simon Matoori
(Université de Montréal)
Chair



Jill Steinbach-Rankins
(Boehringer Ingelheim)
Co-Chair



Justin Hanes
(Johns Hopkins University)
Board Advisor



Beate Bittner
(Roche)
Industry Representative



Thanh Duc Nguyen
(University of Connecticut)
Secretary



Davide Brambilla
(Université de Montréal)
Treasurer



Helena Almeida
(i3S - Instituto de Investigação)
Student Representative



Natalie Guirguis
(Université de Montréal)
Social Media Team



Priyanshu Bharadwaj
(Université de Montréal)
Social Media Team

Breaking barriers webinar series

CRS
Controlled Release Society

Breaking Barriers

CRS FG Transdermal & Mucosal Delivery Webinar Series

FEB 28, 2023
12 p.m. ET
ZOOM WEBINAR
Meeting ID: 812 0177 0379
Passcode: 777967

DR. BEATE BITTNER
Product Optimization Franchise Leader
Roche

The pivotal role of drug delivery and pharmaceutical sciences in developing high dose subcutaneous dosing regimens for monoclonal antibodies



Hosted by the Transdermal and Mucosal Delivery Focus Group

CRS
Controlled Release Society

Breaking Barriers

CRS FG Transdermal & Mucosal Delivery Webinar Series

APRIL 11, 2023
12 p.m. ET
ZOOM WEBINAR
Meeting ID: 812 8572 5922
Passcode: 264446

DR. CHRISTINE ALLEN
Professor, University of Toronto
Vice President, Ecosystem Development at adMare BioInnovations
*research work conducted at Univ. of Toronto

Harnessing Machine Learning for Drug Formulation Design



Hosted by the Transdermal and Mucosal Delivery Focus Group

CRS
Controlled Release Society

Breaking Barriers

CRS FG Skin & Mucosal Delivery Webinar Series

June 20, 2023
12 p.m. ET
ZOOM WEBINAR
Meeting ID: 834 3867 7141
Passcode: 785270

DR. BRUNO SARMENTO
Principal Investigator and Group Leader
The Institute for Research and Innovation in Health (i3S),
University of Porto, Portugal

The mucosal FcRn is a gateway for no-invasive nanomedicines



Hosted by the Skin and Mucosal Delivery Focus Group

At this CRS Annual Meeting

Tomorrow at 9 PM!

CRS Controlled Release Society

CRS FG Skin & Mucosal Delivery

SPEED NETWORKING EVENT

Tuesday, July 25, 2023
9:00 PM - 10:30 PM ET

Location:
Paris Hotel, Champagne 1 & 2

Join us for the opportunity to interact with a variety of academic and industry members!

Hosted by the Skin and Mucosal Delivery Focus Group



Scientific session

Date: Wednesday, July 26

Session Time: 11:00 am - 1:00 pm

Session Title: Skin and Mucosal Delivery (FG)

Room Location: Champagne 1 & 2

Session Moderator: **Simon Matoori**

Discussion Moderator: **Jill Steinbach-Rankins**

Speakers: **Justin Hanes (Johns Hopkins U), Christine Allen (U of Toronto), Stephen Buckley (Novo Nordisk), Xun Sun (Sichuan U)**

Stay tuned

Become a member (free for CRS members) to receive email updates on all activities

Check out our Twitter page



CRS Focus Group - Transdermal and Mucosal Delivery

@CRS_FG_SkinMuco Follows you

A FG of [@CRSScience](#) on Transdermal and Mucosal Delivery. [@CRS_FG_NANO](#) [@CRS_FG_bMimetic](#) [@CRS_FG_Gene](#) [@CRS_FG_Oral](#) [@CRS_FG_Ocular](#) [@CRS_FG_Immuno](#) [@CRS_FG_Nervous](#)

[ControlledReleaseSociety.org/focus-groups/t...](#) Joined November 2018

204 Following 1,043 Followers

 Followed by Twan Lammers, Natalie Guirguis, and 100 others you follow